Börse:
25,660€
-3,21%
Echtzeit-Aktienkurs Veracyte
Bid:
25,390€
Ask:
25,930€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 1,05 Mrd. EUR (40,86 Mio. x 25,660€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot 1 |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 14,35 | 13,31 | 12,20 | 11,40 |
| KGV | - | - | - | - |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Veracyte Aktie
Börsenkurse Veracyte
| Börse Stuttgart | 25,390€ | 0 | 25,930€ | 0 | 25,660€ | -7,20% |
| Dollar Indikation | 28,302$ | 0 | 28,904$ | 0 | 28,603$ | -7,52% |
| Euro Indikation | 25,390€ | 0 | 25,930€ | 0 | 25,660€ | -3,21% |
Fundamentaldaten der Veracyte Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 92,01 Mio. | -23,00 Mio. | -23,00 Mio. | -0,62 | 0,00% | - | 11,40 |
| 2017 | 71,95 Mio. | -31,00 Mio. | -31,00 Mio. | -0,91 | 0,00% | - | 12,20 |
| 2016 | 65,09 Mio. | -31,36 Mio. | -31,36 Mio. | -1,09 | 0,00% | - | 13,31 |
| 2015 | 49,50 Mio. | -33,70 Mio. | -33,70 Mio. | -1,30 | 0,00% | - | 14,35 |
| 2014 | 38,19 Mio. | -29,37 Mio. | -29,37 Mio. | -1,36 | 0,00% | - | 15,13 |
Profil der Veracyte Aktie
Veracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen